AOCI at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s AOCI?
- Krystal Biotech, Inc. (KRYS) reported AOCI of -$1.62M in Q1 2026.
- How has Krystal Biotech, Inc.'s AOCI changed year-over-year?
- Krystal Biotech, Inc.'s AOCI decreased by 516.2% year-over-year, from $390K to -$1.62M.
- What is the long-term trend for Krystal Biotech, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s AOCI has grown at a 185.4% compound annual growth rate (CAGR), from $6K to $1.14M.
- What does AOCI mean?
- The cumulative total of unrealized gains and losses not included in net income.
- How do you interpret AOCI?
- Fluctuations reflect changes in market conditions, currency exchange rates, or investment portfolio performance rather than core operational results.
- How does AOCI compare across companies?
- Varies based on the company's exposure to international markets and investment portfolios.